ClinicalTrials.gg
TerminatedNCT01117129Updated Mar 28, 2014

A Study of Efficacy of Rituximab [Mabthera/Rituxan] in Patients With Rheumatoid Arthritis Using Magnetic Resonance Imaging of the Hand (RESONAR)

A Phase 4 interventional study of rituximab [MabThera/Rituxan] and placebo in Rheumatoid Arthritis, sponsored by Hoffmann-La Roche. Terminated at 1 site in Spain. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2014-03-28.

Sponsored by Hoffmann-La Roche · Phase 4, Interventional, and Treatment

Why this study was terminated
This study was prematurely terminated as 2 patients were recruited and both of them withdrawn from the study before reaching the primary end point.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
2
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 63 studies testing rituximab in Arthritis, Rheumatoid — 5 open to participants now, 6 under way, 1 of them phase 3. Rituximab · Arthritis, Rheumatoid.

Enrollment
63rd of 63
2 · median 159
Started
2010
with 4 others
Phase 4
14 of 63
3 open now
Registered
27th of 63
by date
Lead sponsor
20 of 63
Hoffmann-La Roche

Among the 63 studies testing rituximab in Arthritis, Rheumatoid, this one is the 63rd largest by enrollment, is one of 5 that started in 2010, is one of 14 in phase 4, and was the 27th registered.

Arthritis, Rheumatoid

3,337 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

5 of the 63 studies testing rituximab in Arthritis, Rheumatoid are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About rituximab

Rituximab: first FDA approval 1997 (RITUXAN), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 63 studies testing rituximab in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

This randomized, double-blind, placebo controlled, parallel group study will assess the efficacy and safety of rituximab [MabThera/Rituxan] in patients with severe active rheumatoid arthritis refractory to at least one anti-TNF treatment, using magnetic resonance imaging (MRI) of the hand for efficacy measurement. Patients will be randomized to receive 2 intravenous infusions 14 days apart of either 1000mg MabThera (group A) or placebo (group B). All patients will receive methotrexate 10-25mg weekly. Patients in group A demonstrating clinical response at week 24 may receive further cycles of MabThera, patients in group B without clinical response will also be treated with active MabThera. Anticipated time on study treatment is up to 2 years. Target sample size is \<50 patients.

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • adult patients, 18-75 years of age
  • active rheumatoid arthritis (DAS28-CRP>3.2)
  • to one or more anti-TNF
  • on stable treatment for RA for >/=4 weeks
  • evidence of erosive disease and/or synovitis in wrist and/or knuckles

Exclusion criteria

Exclusion Criteria:

  • active systemic or local infection
  • previous or current history of any demyelinization process in central nervous system, pancytopenia or aplasic anaemia
  • signs of immunodeficiency, infection or tuberculosis
  • to MRI, such as metal devices, claustrophobia, moderate or severe renal insufficiency, or allergy to contrast agent
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
2 participants (actual)

Study arms

  • Experimental
    A

    Drug: rituximab [MabThera/Rituxan] · Drug: methotrexate

  • Placebo comparator
    B

    Drug: placebo · Drug: methotrexate · Drug: rituximab [Mabthera/Rituxan]

Interventions

  • Drugrituximab [MabThera/Rituxan]

    Drug page: Rituximab

    1000 mg by i.v. infusion on day 1 and 15

  • Drugplacebo

    i.v. infusion on day 1 and 15

  • 10-25 mg weekly

  • Drugrituximab [Mabthera/Rituxan]

    Drug page: Rituximab

    1000 mg by i.v. infusion on day 1 and 15, 2nd and further cycles in patients with (group A) or without (group B) clinical response in cycle 1

06

What researchers measure

Primary outcomes

  1. Bone erosion score on magnetic resonance imaging (MRI) using the rheumatoid arthritis magnetic resonance imaging scoring system (RAMRIS)

    Time frame: 6 months

Secondary outcomes

  1. Synovitis score on MRI using RAMRIS

    Time frame: months 6, 12 and 24

  2. Bone edema score on MRI using RAMRIS

    Time frame: months 6, 12 and 24

  3. Bone erosion score on MRI using RAMRIS

    Time frame: months 12 and 24

  4. Disease activity according to DAS28-CRP

    Time frame: months 12 and 24

  5. Tender or swollen joint count (ACR criteria)

    Time frame: months 12 and 24

  6. Health assessment questionnaire (HAQ)

    Time frame: months 12 and 24

07

Study locations

1 site
  • Barcelona, 08003, Spain
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2010, a primary completion of Jun 2010 and a completion of Jun 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 4, 2010
First posted
May 5, 2010
Start
Apr 2010
Primary completionActual
Jun 2010
CompletionActual
Jun 2010
Last update
Mar 28, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 28, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01117129
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
May 5, 2010
Start date
Apr 2010
Primary completion
Jun 2010
Completion
Jun 2010
Last update
Mar 28, 2014

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rituximab

Start the discussion